Noémie Laverdure

Noémie Laverdure

Auto-generated profile, based on publicly available information

Noémie Laverdure

Department of Pediatric Hepato-Gastroenterology and Nutrition, Femme-Mère-Enfants University Hospital, Hospices Civils de Lyon, Bron, France

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JBJuliette Bardet
Juliette Bardet
NLNoémie Laverdure
Noémie Laverdure
MFMathieu Fusaro
Mathieu Fusaro
CPCapucine Picard
Capucine Picard
LGLorna Garnier
Lorna Garnier
ABAlexandre Belot
Alexandre Belot
The NLRC4 inflammasome is part of the human immune innate system. Its activation leads to the cleavage of pro-inflammatory cytokines IL-1β and IL-18, promoting inflammation. NLRC4 gain-of-function (GOF) mutations have been associated with early-onset recurrent fever, recurrent macrophagic activation syndrome and enterocolitis. Herein, we describe two new patients with NLRC4 mutations. The first case presented with recurrent fever and vasoplegic syndrome, gut symptoms and urticarial rashes initially misdiagnosed as a severe protein-induced enterocolitis syndrome. The second case had recurrent macrophage activation syndrome (MAS) and shock, suggesting severe infection. We identified two NLRC4 mutations, on exon 4, within the nucleotide-binding protein domain (NBD). After a systematic review of NLRC4 GOF mutations, we highlight the wide spectrum of this disease with a limited genotype–phenotype correlation. Vasoplegic shock was only reported in patients with mutation in the NBD. Diagnosing this new entity combined with gastrointestinal symptoms and vasoplegic shocks is challenging. It mimics severe allergic reaction or sepsis. The plasma IL-18 level and genetic screening are instrumental to make a final diagnosis.

7 June 2021 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
JDJérôme Dumortier
Jérôme Dumortier
SRSylvie Radenne
Sylvie Radenne
Nassim KamarNassim Kamar
Nassim Kamar
FCFilomena Conti
Filomena Conti
AAArmand Abergel
Armand Abergel
TNThe French Microsporidiosis Network
The French Microsporidiosis Network

1 January 2018 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
RBRomain Barnault
Romain Barnault
TLThomas Lahlali
Thomas Lahlali
MPMarie-Laure Plissonnier
Marie-Laure Plissonnier
CRCristina Romero-López
Cristina Romero-López
NLNoémie Laverdure
Noémie Laverdure
RPromain parent
romain parent

28 October 2025 in Digestive and Liver Disease
Verified
Journal Article
Closed access
OBOlivier Boillot
Olivier Boillot
EWEmma Wischlen
Emma Wischlen
VDValérie Dubois
Valérie Dubois
SCSophie CHOPINET
Sophie CHOPINET
NLNoémie Laverdure
Noémie Laverdure
JDJérôme Dumortier
Jérôme Dumortier

15 May 2023 in Clinics and Research in Hepatology and Gastroenterology
Verified
Journal Article
Closed access
EWEmma Wischlen
Emma Wischlen
NLNoémie Laverdure
Noémie Laverdure
DEDomitille Erard
Domitille Erard
BRBarbara Rohmer
Barbara Rohmer
OBOlivier Boillot
Olivier Boillot
JDJérôme Dumortier
Jérôme Dumortier

9 June 2025 in Liver Transplantation
Verified
Journal Article
Closed access
EWEmma Wischlen
Emma Wischlen
OBOlivier Boillot
Olivier Boillot
CRChristine Rivet
Christine Rivet
ALAlain Lachaux
Alain Lachaux
RBRaymonde Bouvier
Raymonde Bouvier
NLNoémie Laverdure
Noémie Laverdure
Metabolic dysfunction–associated steatotic liver disease is becoming an increasingly frequent cause of chronic liver disease in children. It has been reported as a complication of liver transplantation in adults but remains poorly evaluated in liver-transplanted children. The aim of this study was to assess the prevalence and characteristics of steatotic liver disease in a large cohort of liver-transplanted children and to identify factors associated with it. In this single-center study of patients with pediatric liver transplants (n=122) with a median follow-up time of 14.0 years, steatosis was found in 41 protocol biopsies (33.6%). The median time to the discovery of steatosis was 5.0 years posttransplantation, with a median age of 9.0 years at the time of diagnosis. Steatosis was predominantly mild to moderate and tended to resolve spontaneously on subsequent biopsies (48.8% of cases showed resolution). Steatosis mostly corresponded to metabolic dysfunction–associated steatotic liver disease (56.1%), but other patients had cryptogenic steatosis. The study found no association between the presence of steatosis and the immunosuppressive regimen, but a significant association between the onset of steatosis and an older donor age ( p <0.001). Therefore, steatotic liver disease is a noteworthy histological feature during the follow-up of pediatric liver transplant recipients, yet it had a low burden on the health of the patients in this cohort. However, it needs to be monitored in the context of the increasing prevalence of metabolic syndrome.